Search results
Results from the WOW.Com Content Network
If approved, dapoxetine will be marketed in the US by Ortho McNeil pharmaceutical, Inc. Ortho McNeil and Janssen-Ortho Inc, or Janssen-Cilag are all units of Johnson & Johnson. As at 2005, dapoxetine was in phase III clinical trials, pending review by the FDA. [38] Dapoxetine has been marketed and approved in more than 50 countries. [39]
This is a list of investigational antidepressants, or drugs that are currently under development for clinical use in the treatment of depression but are not yet approved. Specific indications include major depressive disorder , treatment-resistant depression , dysthymia , bipolar depression , and postpartum depression , among others.
Paroxetine was the first drug to be approved for social anxiety disorder and it is considered effective for this disorder; sertraline and fluvoxamine were later approved for it as well. Escitalopram and citalopram are used off-label with acceptable efficacy, while fluoxetine is not considered to be effective for this disorder. [ 22 ]
It can, according to the FDA. Clinical trials reported that headache was actually the most common side effect of Viagra, which can create the right environment for headaches through its ability to ...
FDA approval date: December 29, 1987 [9] December 30, 1991 [9] December 29, 1992 [9] December 5, 1994 July 17, 1998 [9] August 14, 2002 [9] Mechanism of action.
This is a list of investigational sexual dysfunction drugs, or drugs that are currently under development for clinical treatment of sexual dysfunction but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. This list was last comprehensively updated in June 2017.
Duloxetine was approved for use of stress urinary incontinence (SUI) in the EU in 2004. [7] In 2005, Lilly withdrew the duloxetine application for stress urinary incontinence (SUI) in the US, stating that discussions with the FDA indicated "the agency is not prepared at this time to grant approval ... based on the data package submitted."
Jaypirca was first given accelerated approval by the FDA on Jan. 27 for the treatment of mantle cell lymphoma (MCL), a rare type of blood cancer that starts in white blood cells and spreads to ...